Jump to content

CST - CASTILE RESOURCES LTD


colaiscute

Recommended Posts

  • Replies 22k
  • Created
  • Last Reply

Top Posters In This Topic

  • forrestgump

    1573

  • rog

    1833

  • dr_dazmo

    1257

  • skorpian

    1585

Top Posters In This Topic

Posted Images

In reply to: forrestgump on Thursday 28/02/08 09:45am

Hi forrest,

Good find. These clinical guides and brochures are excellent marketing tools. The evidence for change is very compelling.

wr

tu

 

 

==========================

This clinical guide is intended to provide healthcare professionals with an

 

overview of current clinical information on the use of QuantiFERONÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚®-TB Gold

 

(QFTÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¾ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢) for detecting tuberculosis (TB) infection in children.

 

Quote from this paediatric guide (exc references)

 

Clinical studies have shown that QFT has higher specificity in children than the TST, The specificity of QFT in children has been shown as 100%, compared to 58% for the TST.

 

In addition, QFT has been shown to be effective in malnourished children. As the test produces a numerical result it is not subject to reader variability.

 

 

 

==========================

 

This clinical guide is intended to provide healthcare professionals with an

 

overview of current clinical information on the use of QuantiFERONÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚®-TB

 

Gold (QFTÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¾ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢)ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâہ¡ÃƒÆ’‚ÂÂin patients whose immune system has been compromised

 

by Human Immunodeficiency Virus (HIV) or Acquired Immune

 

Deficiency Syndrome (AIDS).

 

================

 

This clinical guide is intended to provide healthcare professionals with an

 

overview of current clinical information on the use of QuantiFERONÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚®-TB

 

Gold (QFTÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’‚¾ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚¢)ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâہ¡ÃƒÆ’‚ÂÂin individuals currently taking, or being considered for,

 

immunosuppressive therapy such as corticosteroids, DMARDS* and

 

anti-tumor necrosis factor-alpha.

 

Link to comment
Share on other sites

On SBS 6.30pm News today a report claims a new tuberculosis drug has been devevolped.

 

It showed TB patients in South Africa being injected with this new drug, which was developed in Oxford UK.

 

This I think was in response to the WHO report yesterday and the frontal attack needed said Dr Mario Raviglione.

 

What impact will this have for Cellestis and the uptake of test kits?

 

Yet they did mention at the end of the newsclip that the drug would possibly be market ready by 2015!!!!

 

 

Link to comment
Share on other sites

G'day all,

For those wanting to know how it all started, here is a snippet of how Cellestis was born

 

QUOTE
Because of the similarity of bovine TB to the human variety, it wasnÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢t long after BovigamÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s
debut that CSL developed a similar tuberculosis test for humans, called Quantiferon. A huge
breakthrough was the fact that the Quantiferon test required only one visit to the doctor to take
a blood sample, with the results available within 24 hours, compared to the skin test which
required an initial tuberculin injection and a second visit two or three days later to have the
reaction measured and interpreted. Many people, especially those in the lower socioeconomic
group who are most at risk from TB, fail to return to have their test read.
Despite all the obvious advantages, however, there was a danger the Quantiferon human
technology might never have seen the light of day. The high cost of commercialising the product
was a stumbling block for CSL, which later decided to sell off the human application.
And thatÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s when Dr Wood and three of his former TB research colleagues, Tony Radford, Jim
Rothel and Stephen Jones, came to the rescue. ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¹Ãƒƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“The four of us were sitting around having a few
beers and talking about the development of Quantiferon,ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ recalls Dr Wood. ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¹Ãƒƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“We suddenly decided,
ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¹Ãƒƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“why donÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢t we do this ourselves ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ we believe in the technology, we can make this happenÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢.ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢
And happen it did. Tony Radford and Jim Rothel sought private investment funds of about
A$1 million and formed a start-up biotechnology company called Cellestis to buy the
technology from CSL and commercialise Quantiferon. In April, 2001, the company was listed on
the Australian Stock Exchange and since then has gone from strength to strength with a capital
value today of about A$130 million and with a combined number of 45 million tests for TB
occurring each year in Japan, the United States and Europe, the total sales of Quantiferon
worldwide could exceed A$100 million per annum.
The product received a major boost in October 2002 when a Panel Review of the all-powerful
Federal Drug Administration (FDA) in Washington voted unanimously after a six-hour hearing to
approve the use of Quantiferon in the United States. ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¹Ãƒƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“It was a very emotional day,ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢ says Dr Wood,
who accompanied the Cellestis team to Washington and presented the Bovigam background to
the research story. ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’â€Â¹Ãƒƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“There was a lot at stake, and we were all extremely relieved and proud when
the decision was announced.ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢
Quantiferon is now playing a vital part in the fight against TB, which claims three million lives
each year, more than any other infectious disease. One third of the worldÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s population is thought
to be infected with TB, and the emergence of multiple drug resistant strains of the disease coupled
with the increasing incidence of TB in HIV patients has added to the seriousness of the problem.
Link to comment
Share on other sites

In reply to: bing on Thursday 28/02/08 07:09pm

Thanks for the links Bing, very interesting story !

Now back to the slow meltdown of the markets and the struggle for cellestis SP to stay afloat , Qtr by Qtr lets hope hope we have that spike in sales that someone mentioned the other day (next qtr Please, please, please)

Link to comment
Share on other sites

Hi All,

Still more evidence that we are making in roads.

 

Dr_Dazmo

 

http://www.dphhs.mt.gov/PHSD/prevention_op...df/MPHDec07.doc

 

Testing for LTBI For many years the Mantoux tuberculin skin test (TST) has been the standard method to identify persons with TB infection but not yet with TB disease. The TST illicits a delayed hypersensitivity reaction to TB antigens in persons with LTBI. However, a reaction can also be illicited to antigens from non-TB mycobacteria leading to false positive TST results. An alternate test, QuantiFERONÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® - Gold (QFT), has been approved by the FDA and will soon be available through the Montana Public Health Laboratory. [NOTE: Notice of availability of this test will be sent to health care providers in early 2008.]

Link to comment
Share on other sites

It was interesting to read how CSL pulled the plug on QFT for humans- with all the money they have why didn't they pursue it?? Surley the cost would have been minimal for them!!

 

Do/Did they know something we DON't!!??............

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...